ClinicalTrials.Veeva
Menu

Find clinical trials for Prostate Cancer in Durham, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Prostatic Cancer
Cancer
Carcinoma
Hypersensitivity
Adenocarcinoma
Recurrence
Castration-Resistant Prostatic Cancer

Prostate Cancer trials near Durham, NC, USA:

Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer

A Phase 1/2a, open-label, multicenter study of intramuscular (i.m.) PRL-02 depot in participants with advanced prostate cancer....

Enrolling
Prostate Cancer
mCSPC
Drug: docetaxel infusion
Drug: PRL-02 injection

Phase 1, Phase 2

Astellas
Astellas

Durham, North Carolina, United States and 13 other locations

This was a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. Enroll...

Active, not recruiting
Prostate Cancer
Drug: Leuprolide Acetate
Drug: Relugolix

Phase 3

Sumitomo Pharma
Sumitomo Pharma

Raleigh, North Carolina, United States and 107 other locations

purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate...

Enrolling
Metastatic Castration-resistant Prostate Cancer
Drug: BMS-986460

Phase 1

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Durham, North Carolina, United States and 7 other locations

This study seeks to determine the clinical impact of Gene Expression Classifier (GEC) testing in prostate cancer care while also de...

Enrolling
Prostate Cancer
Device: Oncotype Dx Genomic Prostate Score (GPS)
Device: Prolaris
University of Michigan Rogel Cancer Center
University of Michigan Rogel Cancer Center

Chapel Hill, North Carolina, United States and 6 other locations

ipilimumab, cabazitaxel and carboplatin in men with neuroendocrine prostate cancer (NEPC) or other aggressive variants of prostate...

Enrolling
Metastatic Prostate Cancer
Metastatic Prostate Neuroendocrine Carcinoma
Drug: Carboplatin
Drug: Ipilimumab

Phase 2

Andrew J. Armstrong, MD

Durham, North Carolina, United States

This study will enroll prostate cancer patients with an unfavorable diagnosis. Subjects will receive a combination of pembrolizumab...

Begins enrollment this month
Prostate Cancer
Procedure: Radical Prostatectomy
Drug: Short-term androgen deprivation therapy

Phase 2

Daniel George, MD

Durham, North Carolina, United States

inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficie...

Enrolling
Metastatic Castration Resistant Prostate Cancer
Drug: Pembrolizumab

Phase 2

VA Office of Research and Development
VA Office of Research and Development

Durham, North Carolina, United States and 11 other locations

and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemo ...

Active, not recruiting
Metastatic Castration-resistant Prostate Cancer
Drug: abiraterone acetate
Drug: olaparib

Phase 3

AstraZeneca
AstraZeneca

Durham, North Carolina, United States and 131 other locations

radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stimulates a ...

Active, not recruiting
Prostate Cancer
Biological: Aglatimagene besadenovec + valacyclovir
Biological: Placebo + valacyclovir

Phase 3

Candel Therapeutics

Durham, North Carolina, United States and 72 other locations

Locations recently updated

Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2...

Enrolling
Prostate Cancer
Drug: Abiraterone
Drug: Enzalutamide

Phase 1

Amgen
Amgen

Durham, North Carolina, United States and 48 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems